Hope for Ipsen after bleak 2019There is a ray of light for Ipsen following a bleak 2019 after its botulin toxin Dysport was approved on Monday in the UK for upper limb spasticity in children, reported Les Echos on Wednesday (p.20) (APMHE 65710).
Meek has had a mixed time in office, the economic daily continued, saying that he had benefited from decisions taken by his predecessor, Marc de Garidel, who left in 2016.
Old Levothyrox formula to be withdraw from French marketThe old formula of Merck KGaA's Levothyrox (levothyroxine) will no longer be sold in France from September, Le Parisien reported in a brief on Thursday (p.9) (APMHE 65760).
Levothyrox patients appeal decision exonerating MerckPatients who had adverse events after taking the new formula of Merck KGaA's Levothyrox (levothyroxine) are appealing a decision made in April 2019 clearing the pharma for not providing enough information, reported L'Humanité in a brief (p.15) on Tuesday.
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to the latest stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.